BANZEL® is generally covered by Insurance Companies, Medicare and Medicaid. Coverage may change based on the specific type of insurance you have. Ask your Pharmacist about how your insurance will cover BANZEL®.
Eisai offers financial assistance to patients who can’t afford BANZEL®. The Eisai Assistance Program can assist you with understanding your options and can be reached at 1-855-EISAI-4-U (1-855-347-2448). Hours of operation are Monday to Friday, 9 am to 5 pm ET.
Commercial insurance companies include organizations such as health maintenance organization (HMO) plans, managed care organizations, indemnity plans, and others. Many of these provide coverage for BANZEL® (rufinamide). However, specific coverage requirements and limits depend on a patient’s benefits and will vary based on your plan type and healthcare provider. Check with your pharmacy to understand what your coverage for BANZEL® will be.
Commercially insured patients may be eligible for the BANZEL® Savings Card Program where they may pay no more than $25 for their prescription. To learn more about this program, click here.
Medicare is the federal health insurance program for people who are 65 or older, certain younger people with disabilities, and people with End-Stage Renal Disease. Part D covers prescription drugs that you get at the pharmacy and take at home including your BANZEL® treatment. Your pharmacist will be able to help you understand how Medicare will cover your BANZEL® treatments.
Medicaid is a joint federal and state program that helps with medical costs for some people with limited income and resources. Each state sets its own coverage and eligibility rules for its Medicaid program. BANZEL® (rufinamide) is eligible for coverage under most state Medicaid programs. However, coverage and patient out-of-pocket costs will vary from state to state. Your pharmacist will be able to help you understand how your state Medicaid plan will cover BANZEL®.
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record
BANZEL® (rufinamide) is a prescription medication approved for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults
Patients with a history of Familial Short QT syndrome should not be treated with BANZEL®. Talk to your healthcare provider if you are unsure if this affects you or your loved one. BANZEL® has been shown to reduce the QT interval. Caution should be used when administering BANZEL® with other drugs that shorten the QT interval.
All medications to treat seizures, including BANZEL®, may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call your healthcare provider right away if you or your loved one experiences new or worsening symptoms of depression, unusual changes in mood or behavior, thoughts or actions about suicide or self-harm, aggression, agitation, anger, anxiety, or irritability.
Use of BANZEL® has been associated with side effects such as sleepiness or feeling tired, difficulty with coordination, dizziness, and problems with walking or movement.
Do not drive, operate heavy machinery, or do other dangerous activities until you know how BANZEL® affects you. BANZEL® can slow your thinking and motor skills.
— Alcohol, in combination with BANZEL®, may increase or worsen these side effects.
Call your healthcare provider if you or your loved one experiences a rash. This can be a sign of a more serious condition, such as multi-organ hypersensitivity reaction.
You or your loved one should take BANZEL® only as prescribed. Do not stop taking BANZEL® without first talking to your healthcare provider. Stopping BANZEL® suddenly can cause serious problems.
Tell your healthcare provider about all the medications you or your loved one takes, including prescription and non-prescription medications, vitamins, and herbal supplements. Using BANZEL® with certain medications can affect each other, causing side effects.
In studies, the most commonly observed (≥10%) side effects with BANZEL® were headache, dizziness, feeling tired, sleepiness, and nausea.
BANZEL® may make hormonal contraceptives (birth control pills) less effective. Additional non-hormonal forms of birth control are recommended when using BANZEL®.
Healthcare providers should be informed if patients are pregnant or planning on becoming pregnant.
Also, BANZEL® is likely to be passed through breast milk to the baby and could cause serious side effects in the baby. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Patients who are pregnant are encouraged to enroll in the North American Antiepileptic Drug Pregnancy Registry. This can be done by calling the toll-free number 1-888-233-2334. Additional information about the registry can be found at www.aedpregnancyregistry.org.
For more information about BANZEL® please see Prescribing Information.
The information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare professional. All decisions regarding patient care must be made with a healthcare professional, considering the unique characteristics of the patient.
This site is intended for residents of the United States only. Any products discussed herein may have different product labeling in different countries.
BANZEL® is a registered trademark used by Eisai under license from Eisai R & D Management Co., Ltd.